Cefaly Technology, the Liege-based company behind Cefaly, an external neurostimulation device designed to treat and prevent migraines, has recently signed an important contract with the South African company Avacare, to distribute its next-generation product throughout South Africa. Worth €1 million, it represents a great opportunity for the Liege-based company to enter a brand new market.

This contract represents an initial amount of €1 million, and could be revised upwards as soon as distribution is extended to other countries on the African continent.

"This contract represents a great opportunity for Cefaly Technology. And it is also a first for the company. We were not yet present on the African continent. Thanks to this contract, not only will the gates of the South African market open up to us, but also those of the rest of the sub-Saharan continent further down the line. The pharmaceutical group Avacare is actually present in more than 20 countries, mainly situated in sub-Saharan Africa," explained Pierre Rigaux, owner of Cefaly.

The launch of the first next-generation Cefaly in South Africa is scheduled for January 2017 onwards. In this respect, an initial direct setting-up order of 600 Cefaly devices has recently been delivered. More than 130,000 Cefaly devices have been sold throughout the world.

Source: Belga